Cyclolab Ltd strengthens its position in the market
![](/46/pdcnewsitem/07/86/35/800_400.jpg-CycloLab%20Cyclodextrin%20Research-CPhI%20WW%202019%20-%20New%20Business%20Basic%20Package.jpg)
Cyclolab Ltd. is an R&D and cGMP manufacturing company focusing on all aspects of cyclodextrin science, manufacturing and applications for cyclodextrin, Dexolve, Sugammadex, formulation development, custom synthesis, Niemann Pick C.
The Cyclolab Cyclodextrin R&D Laboratory is the world's only all-round cyclodextrin biotech company and has operated as a small R&D company for over 25 years.
Recent changes in the world market and economy revealed the need for a change in the company’s business portfolio, which is why we have decided to share the resources between R&D activity and establishment of manufacturing facilities that enable the production of cyclodextrins in larger scale under GMP circumstances.
To maintain and strengthen our position in the market, CycloLab dedicates special attention to invention and developing patentable technologies, highlighted by the over 130 patents filed by the company so far.
CycloLab committed its operations to serve the pharmaceutical industry by participating in early phase drug development studies (feasibility, formulation optimization, bioequivalence, etc), analysis and GMP manufacturing of various cyclodextrin derivatives to be applied as excipients as well as exploring new applications of CDs such as proteins stabilization, non-viral gene delivery or re-discovery as APIs for several therapeutic areas.
Our goal is to help our partners in the successful development of cyclodextrin-based products via supply of the highest quality cyclodextrins and providing services (analytical, formulation development, custom synthesis or GMP manufacturing). We discover proprietary applications for cyclodextrins and join in collaborations, or out-license these to other companies.
![CYCLOLAB Ltd.](https://www.cphi-online.com/c279404th_S-comp279404.jpg)
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance